TY - JOUR
T1 - Unilateral primary aldosteronism as an independent risk factor for vertebral fracture
AU - the Q-AND-A study group
AU - Yokomoto-Umakoshi, Maki
AU - Sakamoto, Ryuichi
AU - Umakoshi, Hironobu
AU - Matsuda, Yayoi
AU - Nagata, Hiromi
AU - Fukumoto, Tazuru
AU - Ogata, Masatoshi
AU - Ogawa, Yoshihiro
N1 - Funding Information:
This work was supported by Kyushu University Research Activity Support Program, Support for Women Returning from Maternity and Parental Leave.
Funding Information:
Funding information This work was supported by Kyushu University Research Activity Support Program, Support for Women Returning from Maternity and Parental Leave. We thank the medical staff of Kyushu University Hospital Department of Endocrinology, Metabolism, and Diabetes for their support.
Publisher Copyright:
© 2019 John Wiley & Sons Ltd
PY - 2020/3/1
Y1 - 2020/3/1
N2 - Context: Primary aldosteronism (PA) is known to increase vertebral fracture (VF), although the detailed mechanism remains to be elucidated. We hypothesized that the PA subtype is associated with VF. Objective: To evaluate whether unilateral PA is associated with the prevalence of VF. Design: This was a retrospective cross-sectional study in a single referral centre. Patients: We identified 210 hypertensive patients whose clinical data were available for case-detection results. One hundred and fifty-two patients were diagnosed with PA using captopril challenge tests. Measurements: We measured the prevalence of VF, according to PA subtype. Results: One hundred thirteen patients with PA were subtype classified by adrenal vein sampling. Of these, 37 patients had unilateral PA, 76 patients had bilateral PA, 58 patients had non-PA; 39 patients with PA were not subtype-classified. Patients with PA had a higher prevalence of VF (29%, 44/152) than those with non-PA (12%, 7/58; P =.011). Moreover, unilateral PA had a higher prevalence of VF (46%, 17/37) than bilateral PA (20%, 15/76; P =.021). There was no significant difference in the prevalence of VF between bilateral PA and non-PA. Unilateral PA was an independent risk factor for VF after adjusting for age and sex (OR: 3.16, 95% confidence interval: 1.12-8.92; P =.017). Among patients with unilateral PA, serum cortisol concentrations after 1-mg dexamethasone suppression test were higher in those with VF (1.32 ± 0.67 g/dL) than those without (0.96 ± 0.33 g/dL; P =.048). Conclusions: Unilateral PA is an independent risk factor for VF.
AB - Context: Primary aldosteronism (PA) is known to increase vertebral fracture (VF), although the detailed mechanism remains to be elucidated. We hypothesized that the PA subtype is associated with VF. Objective: To evaluate whether unilateral PA is associated with the prevalence of VF. Design: This was a retrospective cross-sectional study in a single referral centre. Patients: We identified 210 hypertensive patients whose clinical data were available for case-detection results. One hundred and fifty-two patients were diagnosed with PA using captopril challenge tests. Measurements: We measured the prevalence of VF, according to PA subtype. Results: One hundred thirteen patients with PA were subtype classified by adrenal vein sampling. Of these, 37 patients had unilateral PA, 76 patients had bilateral PA, 58 patients had non-PA; 39 patients with PA were not subtype-classified. Patients with PA had a higher prevalence of VF (29%, 44/152) than those with non-PA (12%, 7/58; P =.011). Moreover, unilateral PA had a higher prevalence of VF (46%, 17/37) than bilateral PA (20%, 15/76; P =.021). There was no significant difference in the prevalence of VF between bilateral PA and non-PA. Unilateral PA was an independent risk factor for VF after adjusting for age and sex (OR: 3.16, 95% confidence interval: 1.12-8.92; P =.017). Among patients with unilateral PA, serum cortisol concentrations after 1-mg dexamethasone suppression test were higher in those with VF (1.32 ± 0.67 g/dL) than those without (0.96 ± 0.33 g/dL; P =.048). Conclusions: Unilateral PA is an independent risk factor for VF.
UR - http://www.scopus.com/inward/record.url?scp=85078680683&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078680683&partnerID=8YFLogxK
U2 - 10.1111/cen.14145
DO - 10.1111/cen.14145
M3 - Article
C2 - 31868939
AN - SCOPUS:85078680683
SN - 0300-0664
VL - 92
SP - 206
EP - 213
JO - Clinical Endocrinology
JF - Clinical Endocrinology
IS - 3
ER -